Background <p>Glioblastoma (GBM) is the most aggressive form of cancer of the central nervous system. Despite advances in immunotherapies and standard-of-care treatments for GBMs, clinical outcomes remain limited—owing to the immunosuppressive tumor microenvironment and the intrinsic resistance of GBM to conventional approaches. As a result, there is growing interest in rational combination strategies, particularly those pairing oncolytic viruses with immune-based…
Infectious bursal disease virus (IBDV) as a novel oncolytic virotherapy in glioblastoma
Journal for ImmunoTherapy of Cancer | | Tur-Planells, V., Bykov, Y., Dawodu, G., Garcia-Romero, N., Izpura-Luis, S., Perez-Rodriguez, L., Rius-Rocabert, S., Palacin-Aliana, I., Arranz-Herrero, J., Marquez-Leiva, I., Monago-Sanchez, A., del Rio, M.-L., Rodriguez-Barbosa, J.-I., Cano-Ochando, J., Garcia-Sastre, A., Lozano-Ojalvo, D., Nistal-Villan, E., Ayuso-Sacido, A., Cuadrado-Castano, S.
Topics: brain-cancer, new-technology, research
Read the full article at Journal for ImmunoTherapy of Cancer